ps88 casino login MacKenzie Scott continues to make medical debt relief a priority in her mysterious giving. This week, Undue Medical Debt, formerly RIP Medical Debt, announced it had received a rare third gift — $50 million — from the billionaire philanthropist, signaling her satisfaction with the group’s efforts to purchase medical debt in bulk from hospitals and debt collectors. Scott has donated a total of $130 million to the organization since 2020. Medical debt is increasing despite having some form of medical insurance. Nearly people are unable to pay their medical bills, according to Third Way, a left-leaning national think tank. Overall, Americans owe about in medical debt, with historically disadvantaged groups shouldering the bulk of the burden. Lower-income people, people with disabilities, middle-aged adults, Black people, the uninsured, and people living in rural areas are among the groups most likely to be affected by medical debt, according to the . Undue Medical Debt buys debt at a discounted price, estimating that it erases about $100 in debt for each $1 donated. The group also collaborates with policymakers to encourage the adoption of measures to curb what people owe for medical care. Scott first gave Undue Medical Debt a $50 million donation in 2020, followed by a $30 million donation in 2022. With that money, the group has relieved nearly $15 billion in debt for more than 9 million people, CEO Allison Sesso said. That’s a significant leap from the $1 billion in debt relieved from 2014 to 2019, she noted. “I’m frankly astounded by this most recent gift from MacKenzie Scott and feel proud to be a steward of these funds as we continue the essential work of dismantling the yoke of medical debt that’s burdening far too many families in this country,” said Sesso. The continued funding has allowed Sesso “to not have to worry about my next dollar,” she said, and “think more strategically about the narrative around medical debt — she has helped us push that conversation.” Undue Medical Debt was started in 2014 by two former debt collection executives, Jerry Ashton and Craig Antico, who were inspired by the Occupy Wall Street movement’s advocacy for debt relief. Growth initially was slow. But with Scott’s gifts, the nonprofit has been able to staff up, produce more research, and develop relationships with policymakers who have pushed for changes to hospital billing practices to relieve debt and prevent people from accumulating it in the first place, Sesso said. Undue Medical Debt’s public policy arm has worked with lawmakers in North Carolina, which became the first state to offer Medicaid payments to hospitals that agree to adopt debt relief measures, she said. The policy change followed the publication of a from Duke University, which found that one in five families in the state had been forced into collections proceedings because of medical debt. Since 2020, the organization’s staff has grown from three to about 40, Sesso said. Those hires included an anthropologist who collects stories from people set back by medical debt to inform the group’s research and advocacy work. Scott’s gifts also have helped improve Undue Medical Debt’s technology to identify people eligible for debt relief and to find hospitals from which it can purchase medical debt, among other things, Sesso said. “This coming year, because of this MacKenzie Scott grant, we’ll be able to add more people, making sure that we can support that growth on an ongoing basis,” Sesso said. Few repeat grantees Few organizations have gift from Scott. Other multi-grant recipients include Blue Meridian, an intermediary group that has directed to nonprofits around the world, and GiveDirectly, which provides no-strings-attached cash payments to low-income people globally. GiveDirectly has received from Scott since 2020. Blue Meridian has not disclosed amounts for the four gifts it’s received since 2019. Scott’s contributions to those two organizations were for specific causes like GiveDirectly’s U.S. poverty relief fund, said Christina Im, a senior research analyst at the Center for Effective Philanthropy. In the case of Undue Medical Debt, the timing of Scott’s first gifts in 2020 and 2022 seemed to correspond with COVID-relief efforts, she said. Scott, the former wife of Amazon founder Jeff Bezos, is worth an estimated but provides few details about her grantmaking decisions. Without further information, it’s hard to know what prompted this third donation to Undue Medical Debt, but Scott has said in public statements that she wants to help those who are most in need and bear the brunt of societal ills, said Elisha Smith Arrillaga, the Center for Effective Philanthropy’s vice president for research. “I have not seen a lot of other folks funding in this area,” Smith Arrillaga added. Anger over health care costs Scott’s latest gift to Undue Medical Debt comes amid national debates about medical insurance and the cost of medical treatments. The murder of UnitedHealthcare CEO Brian Thompson on December 4 in Midtown Manhattan has heightened these conversations, with some lionizing the man who allegedly committed the crime. “That’s no way to get change, full stop,” Sesso said in reference to Thompson’s murder. “But I think the anger around insurance companies and having access to care is very clear.” The U.S. has one of the health care systems in the world. And the amount of medical debt carried by individuals seems to be increasing, noted Adam Searing, a public interest attorney and associate professor at Georgetown University, where he focuses on Medicaid and other health coverage programs. Searing previously served for 17 years as director of the Health Access Coalition at the nonprofit North Carolina Justice Center, advocating for the uninsured and underinsured. During that time, he heard from people losing their homes due to liens from hospitals. Sometimes those liens could be delayed, but it still meant that the debtors couldn’t pass those homes along to their children or grandchildren, he said. “Those stories stuck with me,” he said. “It really has an impact on families.” Relieving debt allows people to get their lives back on track and become financially secure after a major illness or series of expensive bills, Searing said. For philanthropists, it’s also a cause that is largely nonpartisan. Scott shining a spotlight on the issue is undoubtedly “a good thing,” he said. “I think it will have a big effect.” _____ is a senior writer at the Chronicle of Philanthropy. This article was provided to The Associated Press by the Chronicle of Philanthropy as part of a partnership to cover philanthropy and nonprofits supported by the Lilly Endowment Inc. The Chronicle is solely responsible for the content. For all of AP’s philanthropy coverage, visit . Stephanie Beasley Of The Chronicle Of Philanthropy, The Associated PressTwelve people were injured when a California cop lost control of his motorcycle and crashed into spectators at the annual Palm Springs Festival of Lights Parade on Saturday. Those hurt included a child and and older couple, and witnesses described the grisly scene that unfolded after the officer revved his engine and zoomed along downtown North Palm Canyon Drive around 6 p.m., according to the local Desert Sun newspaper. "We did see him pop a wheelie and all of a sudden he went sideways and skid all the way over there," Veronica Ortiz of Pittsburg, California, said. After losing control, the cop "let go of the bike and it went straight into the crowd," Ortiz said. Viewer video shows the moment a Palm Springs police officer crashes into the crowd at the Festival of Lights Parade. 10 people were injured including the officer. We'll have the latest updates tonight at 10 and 11 pm Details: https://t.co/3vx2ZZTmmI pic.twitter.com/M6y9VMuSFH Byron Ruvalcaba of Riverside, California, said that he raced to the accident scene and that one of the cop's hands appeared to have been severed. Ruvalcaba also said outraged paradegoers were yelling at the officer, who was recorded on cellphone video. He was seen zipping past another motorcycle cop who was riding in a circle in the street. "I was telling my partner here that they were going dumbly fast," Ruvalcaba said. "To my eyes, they were going recklessly. My guess is 25 to 35 miles per hour." Palm Springs Public Information Officer Kitty Alvarado dismissed as "rumor" the allegation that the cop intentionally tried to balance his moving motorcycle on its rear wheel and said the crash would be investigated by the California Highway Patrol , the Desert Sun said. On Sunday afternoon, Palm Springs Police Chief Andy Mills identified the injured officer as Kenneth Merenda and said he was "alert and conversant" when Mills and others visited him in the hospital earlier in the day. "I am happy to report he will likely recover mobility in his hand," Mills wrote on his personal Facebook page. "Kenny expressed deep concern for all of those injured and wishes them a full and speedy recovery." Merenda was hired in March 2018, the Palm Springs Police Department said on Facebook at the time. In addition to Merenda, 11 other people were taken to the hospital and two were still receiving treatment, Mills said. Mills, who earlier said he was "truly sorry" for the crash, said he was "aware of social media accounts containing video of the accident." "There is also video of officers demonstrating traffic control maneuvers," Mills wrote. "All of the video available to us will be analyzed and included in the investigation conducted by the California Highway Patrol. Once I have a full understanding of what took place, what caused the accident, and what we could have done differently, I will report back to the community our findings."Army-Navy game has added buzz

Last month, Cynthia Erivo and Ariana Grande created social media’s new favorite meme during an interview with journalist Tracy Gilchrist as they promoted their movie musical, "Wicked." One exchange from the conversation went massively viral after Gilchrist mysteriously informed the film’s stars that fans were “holding space” for the lyrics of “Defying Gravity,” one of the musical’s most iconic songs. Gilchrist asked Grande and Erivo if they knew that “people are taking the lyrics of ‘Defying Gravity’ and really holding space with that and feeling power in that,” which prompted an emotional response from Erivo. Neither of them seemed to know exactly how to reply, and Grande took hold of Erivo’s finger as they looked at one another. In a new " Variety " feature with director Jon M. Chu, they discussed the moment and what was going on in their minds. “I was surprised, because I had no idea. I hadn’t been looking that much,” Erivo said. At the time, Gilchrist asserted that she had seen people treating the song with reverence because she works in “queer media.” “I honestly didn’t know what that meant—am I also in queer media, maybe?” Erivo explained. “Work! Let’s both be there.” Grande chimed in, “I didn’t know what any part of it meant. I didn’t understand the first sentence, and then I definitely didn’t understand how you responded. And I just wanted to be there. Because I knew something big was happening, and I didn’t know how to be there.” “After a while, I didn’t know how to be there,” Erivo replied. About the finger grab, Grande said, “I’m going to grab this, because she looks like you might need something. I don’t know what the tapping was about.” Erivo then said it was simply “tension.” Grande praised Gilchrist despite the shared confusion in the moment, saying, “She’s also an amazing interviewer and a lovely person. That goes without saying...I feel really relieved that the world had the same experience with this moment that I did, because I felt like, ‘Oh, I’m not broken.’” After the clip first went viral, Gilchrist clarified her meaning with Variety , saying, “‘Holding space’ is being physically, emotionally and mentally present with someone or something,” and that people were “finding solace or inspiration” in the song following Donald Trump’s election.

Brian Stanley’s wife Caroline Dwane Stanley resigns from Sinn Féin after party fall-out

A nuclear energy start-up backed by the billionaire entrepreneur Sam Altman has agreed a data centre tie-up to help meet the rising power demand from artificial intelligence technologies. Oklo, the California-based developer of advanced nuclear technology, has signed an agreement to supply as much as 12 gigawatts of electricity to Switch, the Las Vegas-based data centre operator. The non-binding agreement runs through 2044. Oklo will develop nuclear reactors, called the Aurora powerhouse, which each have a maximum power level of 15 megawatts of electricity according to the US Nuclear Regulatory Commission. Altman, 39, is the co-founder and chief executive of OpenAI, the maker of ChatGPT that has fuelled a frenzy around generative AI. Oklo went public in May through a merger with Altman’s blank-cheque firm.

ABC has made the holiday season a little brighter thanks to The Great Christmas Light Fight . Season 12 is currently underway with more elaborate and unique displays. Even though Carter Oosterhouse has been judging for more than a decade, the longtime judge continues to be impressed. The construction expert and interior designer Taniya Nayak has the difficult task of deciding who out of the four families they visit in each episode takes home $50,000 and the coveted trophy. Here Oosterhouse talks about the show’s longevity and what his residence looks like during the holidays with his wife, actress Amy Smart . It’s amazing how this show has become such an annual holiday tradition for families to watch together. Carter Oosterhouse: The Great Christmas Light Fight is the gift that keeps on giving. The more we are on, the more people come up to me at the airport and reflect on how it’s a tradition for them. They tell me, “We know it’s Christmas time when we see this show come on air.” The family programming this embodies is so sweet and perfect for the holiday season. You have the holiday movies on, which are nostalgic and fun. This is a little bit different, yet gives the same moment for families to gather and have a nice little night at home. How would you say your judging eye has evolved? That’s a good question. I think sometimes as a judge you don’t even realize how these displays continue to get better. And it’s not just bigger. It’s more than more lights. I always say I can pick the winner right when the lights go on, but that’s not always true because now what I’ve seen is the creativity level has skyrocketed. People are more and more creative than ever before. It’s not just about putting lights on a tree or making sure the balance is correct or the color profile is engaging and interesting. It’s really about creativity. What that means is people are starting to tell stories with their lights. That’s fascinating. In scripted or nonscripted TV, it’s all about telling a story. When you watch something, that is why you keep going back to it. Now these families with these light displays are telling stories. As the viewer, it’s so much more dynamic and interesting to the point you have to scratch your head and say, “I’m blown away. I’m shocked. Just when you think you’ve seen them all, you haven’t.” Technology has also advanced within these displays through computer programming and drones. The technology is there and every year it gets better. Sometimes we do have people who are extremely good with computers and putting light and synchronized lights together, but that’s not always the winner. I don’t want to say it’s usually not the winner, but it seems to me what I have learned is over time I go back to the creative ones. Those are going to be the winners. If they can throw tech in there, even better because it makes it faster, more efficient maybe, and more interesting to some degree. As far as technology goes, every year we’re seeing something different. The light fighters who have been doing it for decades and are at the forefront of this technology, really geek out over that. I do too. I love learning more about it. Then some people who are doing it for the first time knock your socks off because they have no frame of reference. They just want to do something they want to do and in their mind is really cool. I’m always amazed at the dedication of these participants. The light fighters work extremely hard. They are very diligent with what they are doing. The families are in the grind. When September comes around, they are starting to put their lights up and it’s all hands on deck. It’s a lot of work. As a judge too, I want to make sure I applaud them and give them the credit they deserve. It is impressive to see the lengths they go. These guys are beyond the next level. They know the drill. They take the kids to school, go to work, and then come home to start working on their display at all hours of the night. Then they get up the next day and do the same thing. The cool thing is I’d say 99 percent of the people are happy to do this for their community. That’s the best part. On your travels, have there been places you never thought about going but are glad you went? For Trading Spaces , we traveled all over the United States. I think that was the indoctrination of a really crazy travel schedule. I’d say the good thing is I can go back to some of these areas. To your point, I do get to see areas that have lit up these lights or sometimes they are theme parks because we do heavyweights as well. We get into bigger areas that have the capability of dressing it up. Those are eye-opening. I’m in this last round of shooting right now where there are plenty of places I’ve said, “I want to bring my daughter back here.” That’s a sign they’ve done a really good job. You and Taniya are solo judging in these episodes, but do you talk much? We touch base a couple of times during the season and before. It’s funny because it is all very similar for us. There is a progression of what these light fighters are doing. I always feel like I can figure it out if they are going to be a top tier when the lights go on. Lately, I feel as you’ve gotten into it, this is not what I expected at all and even better. That’s fun. Taniya and I have been on the same page with all that. Does this being known for this show put pressure on you at home to deliver a good display? Does Amy get you to work? Good question. It used to be my wife saying, “So what are we doing? Why aren’t we having any lights?” I say, “I am the judge of The Great Christmas Light Fight . I feel like I would not do a service and carry out the oath of being a judge and fail miserably putting lights up.” Usually, when I get home it’s a lot closer to Christmas. So, we do the inside. I’ve been trying to bring back things people make as a builder and duplicate them. There are a lot of makers out there. You see this guy who has been working in his workshop, who has this crazy Santa Claus walking up a ladder built on a timing system. I think that’s really cool that I want to go home and do that. So I have dabbled in those. You mentioned you’re filming right now for next year. Do you go back and watch the episodes airing as a family at home? We try to, absolutely, when I’m not shooting for next year. We critique. If my daughter is into it, I feel like I’m doing my job. There are tons of shows she can watch, especially during the holidays. I feel if she is into it, I’m doing alright. What’s your go-to Christmas movies to watch? Do you watch Amy’s movie Just Friends ? I feel sometimes people forget that is a Christmas movie. Just Friends , we do watch that. That is definitely a Christmas movie. We go back to all the nostalgic movies. National Lampoon’s Christmas Vacation , we run back through all that. Now there are all these shows, too. Like these Christmas baking shows. I feel like those are of interest to us too. I guess we’re finding shows I never thought I would watch and falling into. Also, being on a show this long, we’re so thankful it has been on the air this long and having such a successful run. You go through a rollercoaster of emotions. Right now, we’re doing great. It’s fun. It’s a new interest not just on the show but on Christmas too. It’s all about being loved ones. This experience has really helped me dive deeper into the whole Christmas world and look at it from other angles compared to when I first started on the show. Anything you can tease about the episodes to come? There is one episode that is coming up, and what was really of interest was the coordination. Not just of the lights but things that these blow molds were doing within the light display. We see a lot of coordination from the tech world, but when you can take traditional elements and mix those into a newer feel, that was really impressive. There was this choir of blow molds in the show, and that was so dynamic because you think, “Wait? Are those blow molds singing to me now?” There was a ton of them. Not only was it visually interesting but to hear it was amazing. What do you want to see from the show moving forward? I do like the heavyweights. Those are really fun to shoot because they are on such a different level. It’s also the community is helping out as well. You just have more people involved. I’d like to see more of those to tell you the truth because there seems to be a lot more people, which creates a bigger energy. That’s not to say the homes don’t do that. We only do one of these types of episodes a year, but I’d love to see more of them. The Great Christmas Light Fight , Thursdays, 8/7c, ABC More Headlines:NEW YORK , Dec. 12, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global biologics contract development and manufacturing organization (CDMO) market size is estimated to grow by USD 10.63 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.46% during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards advent of big data. However, capacity utilization and constraints poses a challenge. Key market players include 3P BIOPHARMACEUTICALS S.L.U, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, particularly in the areas of small molecules and large molecules, including biologics, biosimilars, cancer therapies, monoclonal antibodies, and vaccines. This trend is driven by the increasing demand for specialized expertise and advanced technology in the production of complex biological medicinal products. Niche CDMOs and biopharmaceutical CDMOs are leading the way in the production of biologics, such as recombinant proteins and monoclonal antibodies, using cutting-edge technology like advanced manufacturing technologies, single-use/disposable bioreactors, and automation. The focus on infectious diseases, chronic diseases, and novel therapies, such as immunotherapy, is also driving growth in the market. The disease landscape is constantly evolving, with an increasing focus on evidence-based practice and the development of treatments for conditions like diabetes, geriatric population, and metabolic illnesses. Supply chain management, quality testing, and third-party logistic providers are essential components of the CDMO market, ensuring the production of high-quality biological medications and vaccinations. The use of advanced technology, such as software development and process engineering, is crucial for the production of complex biological molecules, including nucleic acids, cell receptors, and post-translational changes. Pharma clients require CDMOs to provide clinical services, from fermentation and tissue processing to cell bank creation and cell line engineering. The production of biological medications and vaccinations requires a deep understanding of biology, as well as expertise in areas like myelosuppression, cardiotoxicity, renal insufficiency, and neurotoxicity. The CDMO market is expected to continue growing, with a focus on the production of small-molecule drugs, biopharmaceuticals, and biological medications, as well as the development of novel therapies for diseases like allergies, gene therapy, and metabolic syndrome. The use of advanced technology, specialized expertise, and niche CDMOs will be key to meeting the demands of the market and delivering high-quality products to patients. The pharmaceutical industry's technological advancements extend beyond drug research and development to data analytics. This tool is increasingly utilized for clinical data synthesis, expediting the drug development process. Big data is a popular strategy in healthcare, including pharmaceuticals, for informed research and development decisions. Data analytics effectively identifies potential new drug candidates, creates simulation models to assess drug efficacy, pinpoints patient populations through various sources, and monitors potential side effects for early avoidance. Biologics Contract Development and Manufacturing Organizations (CDMOs) leverage these analytics to streamline their services, ensuring efficient and effective drug development. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! Market Challenges The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth due to the increasing demand for biologics, biosimilars, and novel therapies in various disease areas. However, this market faces challenges in producing both small molecules and large molecules, including biologics, monoclonal antibodies, and vaccines. The supply chain for these complex products requires advanced technology, specialized expertise, and collaboration with third-party logistic providers. Biologics CDMOs focus on biological medicinal products, such as recombinant proteins, monoclonal antibodies, and vaccines. They face challenges in producing these products using fermentation, microbial fermentation, and advanced manufacturing technologies, such as single-use/disposable bioreactors. Niche CDMOs specialize in areas like cancer therapies, infectious diseases, and rare diseases, requiring evidence-based practice and cutting-edge technology. The disease landscape includes chronic infectious diseases, ageing, and multisystem functional decline, affecting geriatric populations. These conditions require careful consideration of myelosuppression, cardiotoxicity, renal insufficiency, neurotoxicity, polypharmacy, and mental state. Biopharmaceutical CDMOs must ensure quality testing, automation, software development, process engineering, and biology expertise to meet the needs of pharma clients. The Biologics segment includes monoclonal antibodies, immunotherapy, and gene therapy, requiring tissue processing, cell bank creation, and cell line engineering. Novel therapies, such as nucleic acids, cell receptors, and metabolic illnesses, add complexity to the production process. The challenges of producing these biological molecules and managing their supply chain necessitate collaboration between CDMOs, pharma clients, and other stakeholders. The biologics Contract Development and Manufacturing Organization (CDMO) market is currently challenged by capacity utilization issues. Capacity utilization refers to the ratio of actual production to the potential production when a company's capacity is fully utilized. This measure plays a significant role in manufacturing various therapeutics, particularly biological drugs, due to the intricate production process. Approximately 35% of CDMOs encounter minor capacity utilization constraints during manufacturing, while 20% experience moderate to major constraints. These manufacturing constraints hinder CDMOs from reaching their full production potential, leading to delays in the release of numerous therapeutics. Insights into how AI is reshaping industries and driving growth- Download a Sample Report Segment Overview This biologics contract development and manufacturing organization (cdmo) market report extensively covers market segmentation by 1.1 Mammalian 1.2 Microbial 2.1 Biologics 2.2 Biosimilars 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Mammalian- The mammalian segment holds a significant share in the global biologics Contract Development and Manufacturing Organization (CDMO) market due to the increasing use of mammalian cells in producing therapeutic proteins for various diseases. Mammalian cells, derived from mammalian tissue, are primarily used for growing animal cells in vitro, and there are four main types: fibroblasts, epithelial cells, lymphocytes, and macrophages. Lymphocytes are found in the blood, while the others are found in tissue. Mammalian cell culture is widely used for producing human proteins with high therapeutic potential, such as tissue plasminogen activators, clotting factors, and erythropoietin, which cannot be produced using bacteria or yeasts. Recombinant proteins from mammalian cells are used in therapeutics for conditions like diabetes and cancer. Additionally, mammalian cell culture technology is utilized for bulk vaccine production, contributing to market growth. For instance, Catalent Inc. Signed an agreement in June 2020 to develop a COVID-19 vaccine using its GPEx cell line development technology. Catalent offers comprehensive services, including mammalian cell line development, process development, process validation, formulation development, and drug substance manufacturing, from preclinical to commercial stages. These factors are expected to drive the growth of the mammalian segment in the global biologics CDMO market. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) Research Analysis The Biologics Contract Development and Manufacturing Organization (CDMO) market caters to the production of Biological Medicinal Products, including large molecules such as monoclonal antibodies, biosimilars, cancer therapies, and small molecules. These CDMOs play a crucial role in supplying the pharma industry with high-quality products, serving clients in various therapeutic areas like chronic infectious diseases and diabetes. Advanced manufacturing technologies, like single-use/disposable bioreactors, automation, and software development, are transforming the industry. Smaller, niche BioCDMOs also thrive, offering specialized services in areas like tissue processing and clinical services. The focus on quality testing ensures the production of safe and effective biological medicines, meeting regulatory requirements. Biopharmaceutical companies benefit from the expertise and capabilities of these CDMOs, streamlining their supply chain and accelerating time-to-market for new treatments. Market Research Overview The Biologics Contract Development and Manufacturing Organization (CDMO) market encompasses the production of biologics, including small molecules, large molecules, biosimilars, monoclonal antibodies, cancer therapies, and various specialized therapies such as vaccines, recombinant proteins, and novel therapies. This market caters to the supply chain needs of pharmaceutical clients, focusing on quality testing, third-party logistic providers, and advanced technology. Biologics CDMOs offer specialized expertise in areas like fermentation, microbial fermentation, and advanced manufacturing technologies, including single-use/disposable bioreactors. The market landscape includes a range of niche and biopharmaceutical CDMOs, serving various disease areas like infectious diseases, chronic diseases, and cancer. Cutting-edge technology and evidence-based practice are integral to the biologics CDMO sector, which includes the production of biological medicinal products, small-molecule drugs, and biopharmaceuticals. The biology of cells, tissue processing, cell bank creation, cell line engineering, and post-translational changes are crucial aspects of biologics production. The geriatric population, with ageing and multisystem functional decline, presents unique challenges, including myelosuppression, cardiotoxicity, renal insufficiency, neurotoxicity, polypharmacy, and mental state. Biologics CDMOs address these challenges through automation, software development, process engineering, and biology expertise. The biologics CDMO sector also covers the production of vaccinations, somatic cells, tissues, and various biological molecules, including nucleic acids, cell receptors, and metabolic illnesses like diabetes. Allergy treatments, gene therapy, and therapies for various diseases like cancer, infectious diseases, and metabolic syndrome are also part of the biologics CDMO market. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Type Mammalian Microbial Product Type Biologics Biosimilars Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE TechnavioGoogle is ramping up its push into smart glasses and augmented reality headgear, taking on rivals Apple and Meta with help from its sophisticated Gemini artificial intelligence. The internet titan on Thursday unveiled an Android XR operating system created in a collaboration with Samsung, which will use it in a device being built in what is called internally "Project Moohan," according to Google. The software is designed to power augmented and virtual reality experiences enhanced with artificial intelligence, XR vice president Shahram Izadi said in a blog post. "With headsets, you can effortlessly switch between being fully immersed in a virtual environment and staying present in the real world," Izadi said. "You can fill the space around you with apps and content, and with Gemini, our AI assistant, you can even have conversations about what you're seeing or control your device." Google this week announced the launch of Gemini 2.0, its most advanced artificial intelligence model to date, as the world's tech giants race to take the lead in the fast-developing technology. CEO Sundar Pichai said the new model would mark what the company calls "a new agentic era" in AI development, with AI models designed to understand and make decisions about the world around you. Android XR infused with Gemini promises to put digital assistants into eyewear, tapping into what users are seeing and hearing. An AI "agent," the latest Silicon Valley trend, is a digital helper that is supposed to sense surroundings, make decisions, and take actions to achieve specific goals. "Gemini can understand your intent, helping you plan, research topics and guide you through tasks," Izadi said. "Android XR will first launch on headsets that transform how you watch, work and explore." The Android XR release was a preview for developers so they can start building games and other apps for headgear, ideally fun or useful enough to get people to buy the hardware. This is not Google's first foray into smart eyewear. Its first offering, Google Glass, debuted in 2013 only to be treated as an unflattering tech status symbol and met with privacy concerns due to camera capabilities. The market has evolved since then, with Meta investing heavily in a Quest virtual reality headgear line priced for mainstream adoption and Apple hitting the market with pricey Vision Pro "spacial reality" gear. Google plans to soon begin testing prototype Android XR-powered glasses with a small group of users. Google will also adapt popular apps such as YouTube, Photos, Maps, and Google TV for immersive experiences using Android XR, according to Izadi. Gemini AI in glasses will enable tasks like directions and language translations, he added. "It's all within your line of sight, or directly in your ear," Izadi said. gc/dw